Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Treon

Showing results (21-30 of 323) with videos related to

Pageof 33
Sort By:
Expert Opinion on Drug Safety|March 1, 2021
Reducing treatment toxicity in Waldenström macroglobulinemiaShayna Sarosiek, Steven P Treon, Jorge J Castillo
Hematology/Oncology Clinics of North America|September 8, 2018
Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical ResearchJorge J Castillo, Efstathios Kastritis, Steven P Treon
Current Treatment Options in Oncology|August 24, 2021
How to Sequence Therapies in Waldenström MacroglobulinemiaShayna Sarosiek, Steven P Treon, Jorge J Castillo
Seminars in Oncology|April 30, 2003
Defining Waldenstrom's macroglobulinemiaSteven P Treon, Meletios Dimopoulos, Robert A Kyle
Clinical Lymphoma|March 30, 2005
CHOP plus rituximab therapy in Waldenstrom's macroglobulinemiaSteven P Treon, Zachary Hunter, Andrew R Barnagan
Hematology. American Society of Hematology. Education Program|November 25, 2004
Amyloidosis and Waldenström's macroglobulinemiaMorie A Gertz, Giampaolo Merlini, Steven P Treon
The Oncologist|July 31, 2016
Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based AnalysisAdam J Olszewski, Steven P Treon, Jorge J Castillo
Cancer Treatment and Research|February 7, 2015
Biology, prognosis, and therapy of Waldenström MacroglobulinemiaJorge J Castillo, Irene M Ghobrial, Steven P Treon
Leukemia & Lymphoma|March 17, 2016
Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutationJorge J Castillo, Irene M Ghobrial, Steven P Treon
JAMA Oncology|February 3, 2018
Fitting mSMART Into the Current Clinical Management of Waldenström MacroglobulinemiaJorge J Castillo, Joshua N Gustine, Steven P Treon
Pageof 33

Showing results (21-30 of 323) with videos related to

Sort By:
Pageof 33
Expert Opinion on Drug Safety|March 1, 2021
Reducing treatment toxicity in Waldenström macroglobulinemiaShayna Sarosiek, Steven P Treon, Jorge J Castillo
Hematology/Oncology Clinics of North America|September 8, 2018
Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical ResearchJorge J Castillo, Efstathios Kastritis, Steven P Treon
Current Treatment Options in Oncology|August 24, 2021
How to Sequence Therapies in Waldenström MacroglobulinemiaShayna Sarosiek, Steven P Treon, Jorge J Castillo
Seminars in Oncology|April 30, 2003
Defining Waldenstrom's macroglobulinemiaSteven P Treon, Meletios Dimopoulos, Robert A Kyle
Clinical Lymphoma|March 30, 2005
CHOP plus rituximab therapy in Waldenstrom's macroglobulinemiaSteven P Treon, Zachary Hunter, Andrew R Barnagan
Hematology. American Society of Hematology. Education Program|November 25, 2004
Amyloidosis and Waldenström's macroglobulinemiaMorie A Gertz, Giampaolo Merlini, Steven P Treon
The Oncologist|July 31, 2016
Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based AnalysisAdam J Olszewski, Steven P Treon, Jorge J Castillo
Cancer Treatment and Research|February 7, 2015
Biology, prognosis, and therapy of Waldenström MacroglobulinemiaJorge J Castillo, Irene M Ghobrial, Steven P Treon
Leukemia & Lymphoma|March 17, 2016
Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutationJorge J Castillo, Irene M Ghobrial, Steven P Treon
JAMA Oncology|February 3, 2018
Fitting mSMART Into the Current Clinical Management of Waldenström MacroglobulinemiaJorge J Castillo, Joshua N Gustine, Steven P Treon
Pageof 33